HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shiseido Bets Big On ‘Clean’ Movement With $845M Drunk Elephant Buy

Executive Summary

Drunk Elephant is on track to record more than $100m in fiscal 2019 sales, reflecting compound annual growth north of 120% over the 2016-2019 period. Shiseido is drawn to the prestige brand’s digital savvy and popularity with younger consumers, in part due to its emphasis on “clean” skin care.

You may also be interested in...



Beauty-Focused SPAC Waldencast Announces $1.2Bn Combination With Obagi, Milk Makeup

The special purpose acquisition company, led by a former group president at L’Oreal, seeks to build a “global best-in-class beauty and wellness multi-brand platform,” starting with dermo-cosmetics line Obagi and Milk Makeup, a cult favorite among Gen Zers.

COVID-19 Pandemic: ‘Clean Beauty’ Disruptor Or Reinforcer?

Marketing intelligence firms have different ideas about how the COVID-19 pandemic will impact the “clean beauty" phenomenon.

Cosmetics Market In 2019: ‘Clean’ Beauty Picks Up Speed As Legislative Reform Efforts Chug Along

Cosmetics regulatory reform efforts continued in 2019, which also saw Congress’s first cosmetics safety hearing since 2016. Meanwhile, the “clean” beauty movement gained momentum, fueled by the widely held perception that outdated regulations are allowing cosmetics consumers to be exposed to dangerous chemicals.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel